A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun. The Phase 2 trial, called the COVID-19 anti-CD14 Treatment Trial (CaTT), is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. 

A clinical trial is underway to determine whether people who are highly allergic or have a mast cell disorder are at increased risk for an immediate, systemic allergic reaction to the Moderna or Pfizer-BioNTech COVID-19 vaccines. A systemic allergic reaction to a vaccine occurs in one or more parts of the body beyond the injection site. If such an allergic reaction occurs in study participants, investigators will assess whether the reactions are more frequent in participants who are highly allergic or have a mast cell disorder than in participants with no allergic history.

A study to identify prenatal and early childhood markers of high risk for food allergy and atopic dermatitis, or eczema, as well as biological pathways that lead to these conditions, has begun. The observational study of children from birth to age 3 years will examine the origins of allergic disease by integrating interdisciplinary analyses of data from more than 260 biological and environmental samples and survey responses from each of 2,500 families.

New NIH-supported research shows how two common variations in the KIF3A gene cause an impaired skin barrier that allows increased water loss from the skin.

A NIH study to determine the rate of novel coronavirus infection in children and family members in the United States has begun enrolling participants.

The goal of this study is to further the understanding of the immunologic mechanisms underlying maintenance and loss of beta cell function by evaluating the relationship between longitudinal changes in beta cell function and changes over time in biomarkers known to be associated with a response to immune modulating treatments used in prior clinical trials.

This core serves as a national resource following the specific priorities of the NIAID Radiation and Nuclear Countermeasures Program. Since 2007, the focus has been on the long-term care and study of animals surviving high-dose irradiation. The Core also provides extensive data management services for primate studies, including data and tissue sharing.